NCT03175978View on ClinicalTrials.gov

IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 21, 2018

Primary Completion Date

June 30, 2021

Study Completion Date

September 30, 2021

Conditions
Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicAnemia, Refractory, With Excess of Blasts
Interventions
DRUG

IGF/MTX

765IGF-MTX is supplied as a 5 ml sterile solution at 4.0 µeq per ml 765IGF-MTX concentration in aqueous 10 mM HCl in a 10 ml glass vial

Trial Locations (2)

55101

Regions Cancer Care Center, Saint Paul

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

IGF Oncology, LLC
All Listed Sponsors
lead

IGF Oncology, LLC

INDUSTRY